ClinicalTrials.gg
CompletedNCT06780267Updated Jun 2, 2026

Clinical Study of HRS-2129 for Postoperative Analgesia in Orthopaedics

A Phase 1/2 interventional study of HRS-2129 and HRS-2129 placebo in Postoperative Pain in Orthopaedics, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 248 studies in Pain, Postoperative with a site in China — 78 open to participants now, 80 under way, 3 of them phase 3. Pain, Postoperative · China.

Enrollment
60th of 205
199 · median 132
Started
2025
with 28 others
Phase 1/2
2 of 248
1 open now
Registered
175th of 248
by date

Among the 248 studies in Pain, Postoperative with a site in China, this one is the 60th largest by enrollment of the 205 interventional ones that give a count, is one of 29 that started in 2025, is one of 2 in phase 1/2, and was the 175th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

78 of the 248 studies in Pain, Postoperative with a site in China are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Pain, Postoperative with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for Postoperative analgesia in orthopaedics. To explore the reasonable dosage of HRS-2129 for Postoperative analgesia in orthopaedics.

03

Conditions studied

  • Postoperative Pain in Orthopaedics

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Subjects requiring elective orthopedic surgery
  3. Conform to the ASA Physical Status Classification

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of severe allergies
  2. Subjects with nervous system disease
  3. Subjects with a history of mental illness
  4. Subjects with abnormal liver and renal function
  5. Subjects with poorly controlled hypertensive or hypotensive
  6. :>450ms(male),>470ms(female)
  7. Subjects who screened positive for substance abuse
  8. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
  9. The investigators determined that other conditions were inappropriate for participation in this clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    Treatment group: low\middle\high-dose

    HRS-2129; HRS-2129 placebo

    Drug: HRS-2129 · Drug: HRS-2129 placebo

  • Experimental
    Treatment group:placebo

    HRS-2129 placebo

    Drug: HRS-2129 placebo

  • Active comparator
    Treatment group: positive control

    Tramadol Hydrochloride SR Tablets

    Drug: Tramadol Hydrochloride SR Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Safety:Incidence and severity of AE/SAE

    Time frame: from ICF signing date to day 12 since last dose(14 days)

Secondary outcomes

  1. the Sum of Pain Intensity Differences in Pain Score Over 6hour、12hour、16hour、24hour、48hour、12hour-24hour、24hour-48hour under static and moving condition

    Time frame: 48hours

  2. The response rate of NRS scores under static and moving condition at 24hour and 48hour after the first dose of medication

    Time frame: 48hours

  3. Participant ' satisfaction score for analgesia treatment

    Time frame: 48hours

  4. Investigator satisfaction score for analgesia treatment

    Time frame: 48hours

  5. Time of first use of remedial analgesic medication

    Time frame: 48hours

  6. Cumulative use of remedial analgesics

    Time frame: 48hours

  7. Cmax

    Time frame: 5 days

  8. Tmax

    Time frame: 5 days

  9. AUC0-12h

    Time frame: 5 days

07

Study locations

1 site
  • Sichuan Academy of Medical Sciences - Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Mar 2026, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Mar 11, 2025
Primary completionActual
Mar 19, 2026
CompletionActual
Apr 3, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06780267
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Mar 11, 2025
Primary completion
Mar 19, 2026
Completion
Apr 3, 2026
Last update
Jun 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-2129

Start the discussion